PDK1 and prostate carcinoma: A number of in vitro andin vivo studies in breast and prostate cancer have demonstrated thatMYC amplification or phosphorylation lead to acquired resistance toBEZ235 [81], and Tan andcolleagues used a PDK1 inhibitor to bypass MYC-dependent resistance[81].